Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s

Background. It is unclear whether the integrase inhibitor raltegravir (RAL) reduces inflammation and immune activation compared with ritonavir-boosted protease inhibitors (PIs). Methods. In a prospective, randomized, multicenter clinical trial that included 328 human immunodeficiency type 1 (HIV-1)–...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Infect Dis
Glavni autori: Kelesidis, Theodoros, Tran, Thuy Tien T., Stein, James H., Brown, Todd T., Moser, Carlee, Ribaudo, Heather J., Dube, Michael P., Murphy, Robert, Yang, Otto O., Currier, Judith S., McComsey, Grace A.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2015
Teme:
HIV/AIDS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4542595/
https://ncbi.nlm.nih.gov/pubmed/25904376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ327
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items